2010

18/03/2010
PUBLication IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
NL

15/03/2010
ABLYNX SUCCESSFULLY RAISES €50 MILLION WITH SECONDARY PUBLIC OFFERING - FINAL PRICE: €7.5 PER SHARE
NL

08/03/2010 - Accessible via SPO page (under investor relations)
ABLYNX INTENDS TO RAISE UP TO €57.5 MILLION WITH SECONDARY PUBLIC OFFERING - PRICE RANGE: €7.20 - €7.75 PER SHARE
NL

25/02/2010 - Accessible via SPO page (under investor relations)
ABLYNX PLANS A SECONDARY PUBLIC OFFERING ON EURONEXT BRUSSELS
NL

25/02/2010
ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
NL

22/02/2010
ABLYNX RESPONDS TO PRESS REPORTS
NL

22/02/2010
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST
NL

19/02/2010
ABLYNX RECEIVES €1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061
NL

11/02/2010
ABLYNX WINS PATENT OPPOSITION CASE AGAINST DOMANTIS (GSK)
NL

11/02/2010
ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE
NL

22/01/2010
ABLYNX ANNOUNCES WARRANT EXERCISE
NL

11/01/2010
ABLYNX SUCCESSFULLY GENERATES NANOBODIES® AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME
NL

06/01/2010
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 28TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
NL